

## Spring 2021

### Inside this Issue:

**What's New in  
Neuro-Oncology?  
Let's Talk About It!**


**Philanthropy Today**

**Published Articles by  
Dr. Ekokobe Fonkem and  
the Neuro-Oncology Team**

**The List:  
Current Neuro-Oncology  
Clinical Trials**

## What's New in Neuro-Oncology? Let's Talk About It!

Some amazing things are in the works in the Neuro-Oncology Program at Barrow Neurological Institute. Within the next year, we are starting a neuro-oncology observation fellowship for practicing physicians in sub-Saharan Africa. Through this program, we will host one fellow every six months. Here at Barrow, the fellow will take part in activities, lectures, and programs which will expand their horizons and provide them with knowledge that they may take back to sub-Saharan Africa. Not only will this program allow physicians to improve health care for patients in their home country, it will also enable strong relationships to advance patient care across the world, starting with an African Brain Tissue Bank.



*The survey will  
serve as a guide  
for like-minded  
neuro-oncologists  
across the  
United States.*

## Philanthropy Today

A brain cancer diagnosis is a life-changing event, and many patients and their families understandably become overwhelmed. Every family affected by brain cancer is unique, but every patient can benefit from better communication and collaboration among cancer care providers. After losing her husband, Don, Martha DeGrasse was inspired to support an effort to engage neuro-oncologists and neurosurgeons across the

*Philanthropy Today Continued*

United States. The first step is a survey that will look at the current state of collaboration and barriers to collaboration. The survey and its results will serve as a guide for like-minded healthcare professionals across the United States.

**To support this effort and the work of the Barrow Neuro-Oncology Department, visit:**

<https://giveto.supportbarrow.org/neurooncology>

*“I believe that professional relationships that have a personal dimension to them lead to collaboration and sharing of information,” says Martha. “What I would consider a success is lasting personal relationships between doctors in this field.”*

## Published Articles by Dr. Ekokobe Fonkem and the Neuro-Oncology Team



- **Fonkem E, Peng S, Berens M, Mukherjee S.**  
[Authors' Replay: SMARCB1 Gene Mutation Predisposes to Earlier Development of Glioblastoma: A Case Report of Familial GBM.](#) *J Neuropathol Exp Neurol.* 2021 Feb 22;80(3):290–291
- **Mbi Feh MK, Lyon KA, Brahmaroutu AV, Tadipatri R, Fonkem E.**  
[The need for a central brain tumor registry in Africa: A review of central nervous system tumors in Africa from 1960 to 2017.](#) *Neurooncol Pract.* 2021 Jan 27.
- **Boccia ML, Anyanda EI, Fonkem E.**  
[A Preliminary Report on Quality of Life and Sexual Function in Brain Tumor Patients.](#) *J of Sex Med.* 2021 Feb 6;S1743-6095(21)00174-0.
- **Yuen KC, Mortensen MJ, Azadi A, Fonkem E, Findling JW.**  
[Rethinking the management of immune checkpoint inhibitor-related adrenal insufficiency in cancer patients during the COVID-19 pandemic.](#) *Endocrinol Diab Metab.* 2021;00:e00246.

## The List: Current Neuro-Oncology Clinical Trials

	Study or Protocol Name	Status
1	<b>NCCTG N0577</b> Phase III Intergroup Study of Radiotherapy versus Temozolomide alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma	Open
2	<b>NRG-BN003</b> Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma	Open
3	<b>EA151</b> Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma	Open
1	<b>METIS</b> Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC).	Open
2	<b>Phase 3</b> Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma that Progress/Recure After irradiation and Adjuvant Temozolomide Chemotherapy STELLAR Study	Open
3	<b>Phase 2</b> An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangement _ Startrk-2	Open
4	<b>(Agiros) Phase 3</b> Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation	Open
5	<b>Molecular Analysis</b> for Therapy/Choice (MATCH)	Open
9	<b>OKN-007</b> Open-label Study investigating of OKN-007 combined with Temozolomide in patients with recurrent glioblastoma (Oblato)	Starting Soon
10	<b>EF-32</b> Randomized, open-label study of Tumor Treating Fields (Optune®, 200kHz) concomitant with radiation therapy and temozolomide for the treatment of newly diagnosed glioblastoma	Starting Soon